Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with spontaneous aneurysmal subarachnoid hemorrhage (SAH) defined according to Hunt and Hess scale grade HH5~* Requiring mechanical ventilation in the ICU at the time of enrolment~* Enteral nutrition (EN) in the ICU at time of enrolment~  * If enrolment on day 3 of ICU stay, EN equal to or larger than 80% of total calories in case of supplementary parenteral nutrition (PN) with anticipated 100% EN as of day 4 to 8 of ICU stay~ * If enrolment on day 4 of ICU stay, 100% EN planned for at least 5 days from the time of enrolment~* Patients expected to stay in the ICU for at least 5 days following enrolment~* Age 18 - 75 years~* Glycemic control with intravenous insulin therapy to maintain a target glucose range between 110 mg/dL and 150 mg/dL (6.1 and 8.3 mmol/l)~* Informed consent according to local regulations for decisionally impaired subjects~Exclusion Criteria:~* Patients with septic shock at time of enrolment~* Participation in a clinical trial with any investigational product within 4 weeks before study~* Patients requiring a fibre free diet~* Total or supplementary parenteral nutrition (\> 20% of total calories)~* Known or suspected intolerance or allergy to any component of the study product(s), e.g. galactosemia~* Gastrectomy~* Postpyloric nutrition~* Any clinical condition not allowing enteral nutrition (e.g. emesis, severe reflux, severe diarrhea)~* Known severe heart failure (NYHA class 4)~* Liver insufficiency / failure (male: ALAT \> 150 U/l; female: ALAT \> 120 U/l)~* Acute kidney failure (blood creatinine \> 2.5 mg/dl)~* Body Mass Index \< 18 or \> 35 kg/m²~* Known or suspicion of drug abuse~* Pregnant or breast feeding women~* Patients with diabetes mellitus type I~Exclusion After Enrolment (Withdrawal of Subjects)~* Start of PN with more than 20% of total given energy amount/ day~* Insulin infusion stopped unexpectedly for \> 12h for non-nutritional reasons~* Discharge from ICU~* Intolerable AEs~* Major protocol violation~* Withdrawal of informed consent~* Discontinuation of study treatment for other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diben 1.5 kcal HP (Type: OTHER): Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
- Fresubin HP Energy Fibre (1.5 kcal) (Type: OTHER): Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)

Based on this trial design, predict the completion outcome and termination type (if applicable).